Clinical drug screening reveals clofazimine potentiates the efficacy while reducing the toxicity of anti-PD-1 and CTLA-4 immunotherapy-Reference-Cited by-同舟云学术

Clinical drug screening reveals clofazimine potentiates the efficacy while reducing the toxicity of anti-PD-1 and CTLA-4 immunotherapy

Published:2024-05 Issue:5 Volume:42 Page:780-796.e6
ISSN:1535-6108
Container-title:Cancer Cell
language:en
Short-container-title:Cancer Cell

Author:

Xue Gang,Li Xin,Kalim Muhammad,Fang Jing,Jiang Zhiwu,Zheng Ningbo,Wang Ziyu,Li Xiaoyin,Abdelrahim Maen,He Zhiheng,Nikiforov Mikhail,Jin Guangxu,Lu Yong

Funder

Cancer Prevention and Research Institute of Texas

University of Southern California

National Cancer Institute

Houston Methodist Hospital

National Institute of Allergy and Infectious Diseases

Publisher

Elsevier BV

Reference75 articles.

1. Ipilimumab in combination with nivolumab for the treatment of renal cell carcinoma;Gao;Expet Opin. Biol. Ther.,2018

2. Combination of CTLA-4 and PD-1 blockers for treatment of cancer;Rotte;J. Exp. Clin. Cancer Res.,2019

3. Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma;Hao;Medicine,2017

4. FDA approval summary: Nivolumab with ipilimumab and chemotherapy for metastatic non–small cell lung cancer, A collaborative project orbis review;Vellanki;Clin. Cancer Res.,2021

5. FDA Approval Summary: Nivolumab Plus Ipilimumab for the Treatment of Patients with Hepatocellular Carcinoma Previously Treated with Sorafenib;Saung;Oncologist,2021

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Revolutionizing cancer immunotherapy: The dual role of clofazimine in enhancing efficacy and reducing toxicity;Clinical and Translational Medicine;2024-07

2. Having the cake and eating it? Clofazimine boosts immunotherapy while limiting side effects;Cancer Cell;2024-05

3. Eclipsing Toxicity, Enhancing Efficacy: Clofazimine’s Vanguard in the Realm of Anti-PD-1 and CTLA-4 Immunotherapy;Research;2024-01